First-line anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy in Japanese mucosal melanoma: A retrospective, multicenter study (JMAC study)

被引：0

作者：

Nakamura, Y. ^{[1
]}

Namikawa, K. ^{[2
]}

Yoshikawa, S. ^{[3
]}

Kiniwa, Y. ^{[4
]}

Maekawa, T. ^{[5
]}

Yamasaki, O. ^{[6
]}

Isei, T. ^{[7
]}

Matsushita, S. ^{[8
]}

Nomura, M. ^{[9
]}

Nakai, Y. ^{[10
]}

Fukushima, S. ^{[11
]}

Saito, S. ^{[12
]}

Takenouchi, T. ^{[13
]}

Tanaka, R. ^{[14
]}

Kato, H. ^{[15
]}

Otsuka, A. ^{[16
]}

Matsuya, T. ^{[17
]}

Baba, N. ^{[18
]}

Nagase, K. ^{[19
]}

Inozume, T. ^{[20
]}

机构：

[1] Saitama Med Univ, Dept Skin Oncol Dermatol, Int Med Ctr, Saitama, Japan

[2] Natl Canc Ctr Hosp Tsukiji Campus, Dept Dermatol Oncol, Tokyo, Japan

[3] Shizuoka Canc Ctr, Dept Dermatol, Shizuoka, Japan

[4] Shinshu Univ, Dept Dermatol, Matsumoto, Nagano, Japan

[5] Jichi Med Univ Hosp, Dept Dermatol, Shimotsuke, Tochigi, Japan

[6] Okayama Univ, Dept Dermatol, Okayama, Japan

[7] Osaka Int Canc Inst, Dept Dermatol Oncol, Osaka, Japan

[8] Natl Hosp Org, Kagoshima Med Ctr, Dept Dermatooncol Dermatol, Kagoshima, Japan

[9] Kyoto Univ, Grad Sch Med, Dept Therapeut Oncol, Kyoto, Japan

[10] Mie Univ, Dept Dermatol, Tsu, Mie, Japan

[11] Kumamoto Univ, Dept Dermatol, Kumamoto, Japan

[12] Gunma Univ, Dept Dermatol, Maebashi, Gumma, Japan

[13] Niigata Canc Ctr Hosp, Dept Dermatol, Niigata, Japan

[14] Kawasaki Med Sch, Dept Dermatol, Kurashiki, Okayama, Japan

[15] Nagoya City Univ, Dept Dermatol, Nagoya, Aichi, Japan

[16] Kyoto Univ Hosp, Dept Dermatol, Kyoto, Japan

[17] Asahikawa Med Univ, Dept Dermatol, Asahikawa, Hokkaido, Japan

[18] Univ Fukui, Dept Dermatol, Fukui, Japan

[19] Saga Univ, Dept Dermatol, Saga, Japan

[20] Chiba Univ, Dept Dermatol, Chiba, Japan

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.1431

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1046P

引用

页码：S876 / S876

页数：1

共 50 条

[21] Anti-PD-1 antibody in combination with radiotherapy as first-line therapy for unresectable intrahepatic cholangiocarcinoma
Zhu, Meiyan
Jin, Meng
Zhao, Xiao
Shen, Shunli
Chen, Yihan
Xiao, Han
Wei, Guangyan
He, Qiang
Li, Bin
Peng, Zhenwei
[J]. BMC MEDICINE, 2024, 22 (01)
[22] CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients
Goltz, Diane
Gevensleben, Heidrun
Vogt, Timo J.
Dietrich, Joern
Golletz, Carsten
Bootz, Friedrich
Kristiansen, Glen
Landsberg, Jennifer
Dietrich, Dimo
[J]. JCI INSIGHT, 2018, 3 (13):
[23] Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
Afzal, Muhammad Zubair
Mercado, Rima R.
Shirai, Keisuke
[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
[24] Anti-PD-1 Therapy in Melanoma
Moreno, Blanca Hornet
Parisi, Giulia
Robert, Lidia
Ribas, Anton
[J]. SEMINARS IN ONCOLOGY, 2015, 42 (03) : 466 - 473
[25] Activity of Anti-PD-1 in Murine Tumor Models: Role of "Host" PD-L1 and Synergistic Effect of Anti-PD-1 and Anti-CTLA-4
Korman, Alan
Chen, Bing
Wang, Changyu
Wu, Linda
Cardarelli, Pina
Selby, Mark
[J]. JOURNAL OF IMMUNOLOGY, 2007, 178
[26] Comparison of efficacy between anti-PD-1 antibody monotherapy and nivolumab plus ipilimumab therapy as first-line immunotherapy for advanced mucosal melanoma in Japanese patients: A single-center, retrospective cohort study
Horisaki, Ken
Yoshikawa, Shusuke
Omata, Wataru
Tsutsumida, Arata
Kiyohara, Yoshio
[J]. JOURNAL OF DERMATOLOGY, 2024,
[27] Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
Bowyer, S.
Prithviraj, P.
Lorigan, P.
Larkin, J.
McArthur, G.
Atkinson, V.
Millward, M.
Khou, M.
Diem, S.
Ramanujam, S.
Kong, B.
Liniker, E.
Guminski, A.
Parente, P.
Andrews, M. C.
Parakh, S.
Cebon, J.
Long, G. V.
Carlino, M. S.
Klein, O.
[J]. BRITISH JOURNAL OF CANCER, 2016, 114 (10) : 1084 - 1089
[28] Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
S Bowyer
P Prithviraj
P Lorigan
J Larkin
G McArthur
V Atkinson
M Millward
M Khou
S Diem
S Ramanujam
B Kong
E Liniker
A Guminski
P Parente
M C Andrews
S Parakh
J Cebon
G V Long
M S Carlino
O Klein
[J]. British Journal of Cancer, 2016, 114 : 1084 - 1089
[29] Defining melanoma patients unresponsive to single agent anti-PD-1 therapy but responsive to combination anti-PD-1+anti-CTLA-4 therapy
Edwards, Jarem J.
da Silva, Ines Pires
Ferguson, Angela
Johansson, Peter
Conway, Jordan
Attrill, Grace
Saw, Robyn P. M.
Thompson, John F.
Menzies, Alexander M.
Palendira, Umaimainthan
Long, Georgina, V
Scolyer, Richard A.
Wilmott, James S.
[J]. CANCER RESEARCH, 2020, 80 (16)
[30] Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study
Gauci, Marie-Lea
Boudou, Philippe
Baroudjian, Barouyr
Vidal-Trecan, Tiphaine
Da Meda, Laetitia
Madelaine-Chambrin, Isabelle
Basset-Seguin, Nicole
Bagot, Martine
Pages, Cecile
Mourah, Samia
Resche-Rigon, Matthieu
Pinel, Sylvine
Sassier, Marion
Rouby, Franck
Eftekhari, Pirayeh
Lebbe, Celeste
Gautier, Jean-Francois
[J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2018, 67 (08) : 1197 - 1208

← 1 2 3 4 5 →